Drug Designing: Open Access : Citations & Metrics Report
Articles published in Drug Designing: Open Access have been cited by esteemed scholars and scientists all around the world. Drug Designing: Open Access has got h-index 9, which means every article in Drug Designing: Open Access has got 9 average citations.
Following are the list of articles that have cited the articles published in Drug Designing: Open Access.
| Journal total citations count | 456 |
| Journal impact factor | 1.70 |
| Journal 5 years impact factor | 1.5 |
| Journal cite score | 1.57 |
| Journal h-index | 9 |
| Journal h-index since 2019 | 7 |
Important citations (297)
Effect of thyroid hormones on glucose homeostasis |
|
Tablets manufacturing methods and granulation techniques |
|
Discussion on the issue of sample size determination for a targeted to an untargeted and to a mixed effect model-based clinical trial design |
|
Analytical similarity assessment in biosimilar studies. |
|
Challenging issues in assessing analytical similarity in biosimilar studies |
|
Statistical considerations in demonstrating cmc analytical similarity for a biosimilar product |
|
Statistical approaches to assess biosimilarity from analytical data |
|
On the establishment of equivalence acceptance criterion in analytical similarity assessment. |
|
Sample size requirement in analytical studies for similarity assessment. |
|
On the glycosylation aspects of bio similarity |
|
Pragmatic rules for comparability of biological medicinal products. |
|
on statistical approaches for demonstrating analytical similarity in the presence of correlation |
|
Potent biological agent benzimidazole–a review |
|
Synthesis and biological evaluation of some new benzimidazole derivatives bearing dithiocarbamate moiety as potential cholinesterase inhibitors |
|
A review on recent publications using microwaves in synthesis of biologically active molecules |
|
Acetylcholine esterase inhibitory potential of some benzimidazole derivatives |
|
Statistical and regulatory considerations in assessments of interchangeability of biological drug products. |
|